Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY2922083 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2013
At a glance
- Drugs LY 2922083 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 22 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.